Friday 6 November 2026
Export LH’s income statement to Excel — free account
Labcorp Holdings Inc.
LH Healthcare Diagnostics & Research
Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.
- Revenue
- +6.92%
- EPS
- +3.18%
- Free cash flow
- +44.7%
- Total debt
- +3.21%
Quarter to September 2026, against a year earlier
362.28
5.51
−1.50%
Follow LH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.80 | 23.49 | 23.01 | 25.11 |
P/S ratio |
1.50 | 1.55 | 1.59 | 1.71 | |
P/FCF ratio |
19.40 | 17.41 | 22.16 | 21.60 | |
P/Operating CF |
33.98 | 114.67 | 51.35 | 44.32 | |
P/B ratio |
2.42 | 2.52 | 2.66 | 2.82 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.83 | 1.90 | 2.00 | 2.06 | |
EV/EBITDA |
12.34 | 12.63 | 13.07 | 13.61 | |
EV/Operating CF |
15.54 | 14.82 | 17.49 | 16.55 | |
EV/FCF |
23.69 | 21.31 | 27.76 | 25.97 | |
Quick Ratio |
0.99 | 1.30 | 1.25 | 1.00 | |
Current Ratio |
1.42 | 1.73 | 1.80 | 1.41 | |
Net Debt/EBITDA |
15.83 | 8.87 | 9.16 | 6.92 | |
Debt/Assets |
27.99% | 30.89% | 31.94% | 28.07% | |
Debt/Equity |
0.60 | 0.68 | 0.69 | 0.60 | |
Asset Turnover |
0.76 | 0.77 | 0.78 | 0.78 | |
Operating CF/Net income |
3.73 | 0.69 | 1.49 | 2.15 | |
Capex/Depreciation |
(4.85) | (0.65) | (0.72) | (0.49) | |
Interest Coverage |
4.87 | 6.91 | 7.39 | 6.80 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.30% | 15.58% | 15.47% | 16.05% | |
Intangible Assets out of Total Assets |
0.56 | 0.55 | 0.58 | 0.58 | |
Share Based Compensation of Revenue |
0.84% | 0.90% | 0.94% | 0.81% | |
Graham Net Nets |
(0.28) | (0.26) | (0.27) | (0.24) | |
Graham Number |
156.75 | 164.65 | 169.84 | 173.55 | |
Earnings Yield |
4.20% | 4.26% | 4.35% | 3.98% | |
Free Cash Flow Yield |
5.15% | 5.74% | 4.51% | 4.63% | |
Revenue per Share |
42.26 | 42.98 | 45.67 | 46.98 | |
Operating CF per Share |
7.38 | 2.33 | 5.45 | 6.95 | |
Capex per Share |
(1.39) | (1.38) | (1.59) | (1.99) | |
Free Cash Flow per Share |
5.99 | 0.95 | 3.87 | 4.96 | |
Cash per Share |
6.40 | 11.92 | 1.74 | 3.23 | |
Shareholders Equity per Share |
103.60 | 106.06 | 105.35 | 109.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
103.60 | 106.06 | 105.35 | 109.10 | |
Free Cash Flow |
498.30 | 78.30 | 315.80 | 402.50 | |
Working Capital |
1,197.00 | 1,917.80 | 1,690.30 | 1,146.60 | |
Capital Expenditures |
(115.90) | (113.20) | (129.70) | (161.30) | |
Net Current Asset Value |
(5,752.40) | (5,799.70) | (6,110.60) | (6,110.60) | |
EV/EBIT |
18.41 | 18.67 | 19.15 | 20.00 | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
15.07 | 15.25 | 15.29 | 16.64 | |
| Other line items | |||||
Average Receivables |
2,178.85 | 2,362.50 | 2,390.75 | 2,411.95 | |
Average Payables |
858.30 | 706.80 | 740.75 | 703.25 | |
Average Inventory |
513.95 | 493.00 | 535.15 | 529.95 | |
Average Assets |
18,385.85 | 18,345.45 | 18,296.10 | 18,593.10 | |
Average Common Equity |
8,336.00 | 8,518.00 | 8,539.75 | 8,772.35 |
Columns are period end dates · fundamentals updated 5 Nov 2026